ClinicalTrials.gov
public full text
Public Domain
A Study to Evaluate the Efficacy of Xlear vs. Placebo for Acute COVID-19 Infection
This study aims to find out the efficacy of Xlear nasal spray as an adjunct medication against COVID-19. This encompasses reduction in the number of days to negativization via nasal swab PCR from the average 14 days and early improvement of symptoms.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Xylitol Based Nasal Spray for COVID-19 Treatment#909376
- A Study to Learn About the Use of Paxlovid in Patients With COVID-19 in the Kingdom of Bahrain.#1365260
- Evaluation of the Efficacy of Xylitol Nasal Spray Against SARS-CoV-2#873426
- Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis#889589
- Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia#1210877
Record · ID 1349409
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive